Pharmacokinetics of inhaled colistin in patients with cystic fibrosis - PubMed
F Ratjen 1 ,
Article ImagesClinical Trial
doi: 10.1093/jac/dki461. Epub 2006 Jan 5.
Affiliations
- PMID: 16396919
- DOI: 10.1093/jac/dki461
Clinical Trial
Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
F Ratjen et al. J Antimicrob Chemother. 2006 Feb.
Abstract
Objectives: Inhaled colistin is commonly used in patients with cystic fibrosis (CF), but only limited data are available to define its pharmacokinetic profile.
Patients and methods: We performed a multicentre study in 30 CF patients to assess sputum, serum and urine concentrations after a single dose of 2 million units of colistin administered by inhalation. In a subgroup of patients we also compared the efficacy of two different nebulizers for administration of inhaled colistin.
Results: Serum concentrations of colistin reached their maximum 1.5 h after inhalation and decreased thereafter. Serum concentrations were well below those previously reported for systemic application in all patients. A mean 4.3+/-1.3% of the inhaled dose was detected in urine. Elimination characteristics did not differ significantly from those previously reported for systemic application. A positive correlation was found between forced expiratory volume in 1 s (FEV1) in per cent predicted and both AUC and maximal colistin concentrations in serum (Cmax). Maximum sputum concentrations were at least 10 times higher than the MIC breakpoint for Pseudomonas aeruginosa proposed by the British Society for Antimicrobial Chemotherapy. Although sputum drug concentrations decreased after a peak at 1 h, the mean colistin concentrations were still above 4 mg/L after 12 h. No differences were seen in polymyxin E sputum concentrations, for CF patients between the two nebulizer systems.
Conclusions: The low systemic and high local concentrations of colistin support the use of inhaled colistin in CF patients infected with P. aeruginosa.
Comment in
-
Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
Li J, Nation RL. Li J, et al. J Antimicrob Chemother. 2006 Jul;58(1):222-3; author reply 223. doi: 10.1093/jac/dkl169. Epub 2006 Apr 26. J Antimicrob Chemother. 2006. PMID: 16641116 No abstract available.
Similar articles
-
Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.
Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG. Westerman EM, et al. J Cyst Fibros. 2007 Jul;6(4):284-92. doi: 10.1016/j.jcf.2006.10.010. Epub 2006 Dec 20. J Cyst Fibros. 2007. PMID: 17185047 Clinical Trial.
-
Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP. Yapa SWS, et al. Antimicrob Agents Chemother. 2014 May;58(5):2570-9. doi: 10.1128/AAC.01705-13. Epub 2014 Feb 18. Antimicrob Agents Chemother. 2014. PMID: 24550334 Free PMC article. Clinical Trial.
-
Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. Li J, et al. J Antimicrob Chemother. 2003 Dec;52(6):987-92. doi: 10.1093/jac/dkg468. Epub 2003 Oct 29. J Antimicrob Chemother. 2003. PMID: 14585859
-
Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS, Henig NR. Elborn JS, et al. Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Expert Opin Pharmacother. 2010. PMID: 20426707 Review.
-
Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB. Fiel SB. Expert Rev Respir Med. 2014 Jun;8(3):305-14. doi: 10.1586/17476348.2014.896205. Expert Rev Respir Med. 2014. PMID: 24838090 Review.
Cited by
-
Teney C, Poupelin JC, Briot T, Le Bouar M, Fevre C, Brosset S, Martin O, Valour F, Roussel-Gaillard T, Leboucher G, Ader F, Lukaszewicz AC, Ferry T; PHAGEinLYON Clinic Study Group. Teney C, et al. Viruses. 2024 Jul 5;16(7):1080. doi: 10.3390/v16071080. Viruses. 2024. PMID: 39066242 Free PMC article.
-
Talwar D, Prajapat D, Talwar S, Talwar D. Talwar D, et al. Cureus. 2024 Feb 21;16(2):e54652. doi: 10.7759/cureus.54652. eCollection 2024 Feb. Cureus. 2024. PMID: 38524091 Free PMC article.
-
Appropriate use of colistin in neonates, infants and children: Interim guidance.
Chibabhai V, Bekker A, Black M, Demopoulos D, Dramowski A, du Plessis NM, Lorente VP, Nana T, Rabie H, Reubenson G, Thomas R. Chibabhai V, et al. S Afr J Infect Dis. 2023 Dec 19;38(1):555. doi: 10.4102/sajid.v38i1.555. eCollection 2023. S Afr J Infect Dis. 2023. PMID: 38223435 Free PMC article. No abstract available.
-
Shi R, Fu Y, Gan Y, Wu D, Zhou S, Huang M. Shi R, et al. Front Pharmacol. 2023 Sep 1;14:1222044. doi: 10.3389/fphar.2023.1222044. eCollection 2023. Front Pharmacol. 2023. PMID: 37719858 Free PMC article.
-
Armengol E, Kragh KN, Tolker-Nielsen T, Sierra JM, Higazy D, Ciofu O, Viñas M, Høiby N. Armengol E, et al. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0164122. doi: 10.1128/aac.01641-22. Epub 2023 Mar 1. Antimicrob Agents Chemother. 2023. PMID: 36856424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical